Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002795199 | SCV003021560 | uncertain significance | Saldino-Mainzer syndrome | 2022-07-20 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with IFT140-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces serine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 710 of the IFT140 protein (p.Ser710Ile). |
Ambry Genetics | RCV004064660 | SCV004886173 | uncertain significance | Inborn genetic diseases | 2024-01-23 | criteria provided, single submitter | clinical testing | The c.2129G>T (p.S710I) alteration is located in exon 18 (coding exon 16) of the IFT140 gene. This alteration results from a G to T substitution at nucleotide position 2129, causing the serine (S) at amino acid position 710 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005008744 | SCV005642817 | uncertain significance | Saldino-Mainzer syndrome; Retinitis pigmentosa 80 | 2024-04-10 | criteria provided, single submitter | clinical testing |